Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab

Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and pertuzumab, we developed a high-throughput and ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Schokker, Sandor, Fusetti, Fabrizia, Bonardi, Francesco, Molenaar, Remco J., Mathôt, Ron A.A., van Laarhoven, Hanneke W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531571/
https://www.ncbi.nlm.nih.gov/pubmed/32744170
http://dx.doi.org/10.1080/19420862.2020.1795492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531571/
https://www.ncbi.nlm.nih.gov/pubmed/32744170
http://dx.doi.org/10.1080/19420862.2020.1795492

Ejemplares similares